With mRNA vaccines showing their efficacy in the response to the severe acute respiratory syndrome coronavirus 2-caused COVID-19, a critical role in the success was the lipid nanoparticle (LNP) delivery platform that stabilized the mRNA. LNPs, once administered, will traverse the body’s circulatory system and often end up being processed in the liver, spleen, and kidneys. Scientists have hypothesized the idea of charging LNPs whether positively or negatively to affect where they localized post administration through the addition of an extra lipid within a stable four-lipid formulation. In this study, we focused on the process of optimizing mRNA expression and particle stability in modular five-lipid LNP formulations. The findings indicate that not only are the storage stabilities of five-lipid formulations possible across time and temperature, but the manipulation and optimization of these formulations allow for increased expression of the payload mRNA depending on application.